|
WO2018222351A1
|
|
Triptolide lactone derivatives as immunomodulators and anticancer agents
|
|
CN106794211A
|
|
Polygalacturonase rhamnosan galacturonic acid (PGRG1) composition
|
|
US2016038454A1
|
|
Intravenous formulations of triptolide compounds as immunomodulators and anticancer agents
|
|
CN104387406A
|
|
Triptolide c-ring derivatives as anticancer agents and immune modulators
|
|
WO2006044496A2
|
|
Identification and screening of triptolide target molecules
|
|
US2007244080A1
|
|
Method for Treatment of Inflammatory Disorders Using Triptolide Compounds
|
|
CA2557260A1
|
|
Triptolide lactone ring derivatives as immunomodulators and anticancer agents
|
|
WO2005077008A2
|
|
Methods for isolation of triptolide compounds from tripterygium wilfordii
|
|
WO2005020887A2
|
|
Method for treatment of severe acute respiratory syndrome
|
|
CN1753666A
|
|
Halogenated triptolide derivatives as immunomodulators and anticancer agents
|
|
US6943259B2
|
|
Halogenated triptolide derivatives as immunomodulators and anticancer agents
|
|
WO2004058246A1
|
|
Triptolide derivatives as immunomodulator and anticancer agents
|
|
EP2468277A1
|
|
Triptolide derivatives for modulation of apoptosis and immunosuppression
|
|
EP1390358A1
|
|
Amino acid derivatives of triptolide compounds as immune modulators and anticancer agent
|
|
AU2002237884B2
|
|
Anticancer treatment using triptolide prodrugs
|
|
US6991817B2
|
|
Acid-modified arabinogalactan protein composition
|
|
US6548537B1
|
|
Triptolide prodrugs having high aqueous solubility
|
|
WO0100682A1
|
|
Hematopoietic arabinogalactan composition
|
|
AU6242599A
|
|
Triptolide prodrugs having high aqueous solubility
|
|
EP1375488A1
|
|
Triptolide prodrugs having high aqueous solubility
|
